Utility of SomaSignalTM panels for drug response and monitoring disease progression in patients with advanced fibrosis due to nonalcoholic steatohepatitis

被引：0
|
作者：
Kowdley, Kris [1 ]
Zhu, Kaiyi [2 ]
Xu, Jun [2 ]
Melehani, Jason [2 ]
Boyette, Lisa [2 ]
Watkins, Timothy R. [2 ]
Lim, Sharlene [2 ]
Malkov, Vlad [2 ]
Billin, Andrew [2 ]
Noureddin, Mazen [3 ]
Loomba, Rohit [4 ]
机构：
[1] Liver Inst Northwest, Seattle, WA USA
[2] Gilead Sci Inc, Foster City, CA USA
[3] Houston Res Inst, Houston, TX USA
[4] NAFLD Res Ctr, Div Gastroenterol & Hepatol Med, La Jolla, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-438
引用
收藏
页码：S678 / S680
页数：3
相关论文
共 50 条
  • [1] INCREASED CARDIOVASCULAR AND KIDNEY DISEASE RISK IN PATIENTS WITH ADVANCED FIBROSIS DUE TO NONALCOHOLIC STEATOHEPATITIS
    Corey, Kathleen E.
    Xu, Jun
    Lim, Sharlene
    Zhu, Kaiyi
    Malkov, Vladislav A.
    Melehani, Jason
    Boyette, Lisa
    Watkins, Timothy R.
    Billin, Andrew N.
    HEPATOLOGY, 2023, 78 : S816 - S817
  • [2] Disease Recurrence and Fibrosis Progression in Patients Transplanted for Nonalcoholic Steatohepatitis
    Bhati, Chandra
    Rivera, Maria
    Idowu, Michael O.
    Driscoll, Carloyn
    Kohli, Divyanshoo R.
    Stravitz, R. Todd
    Sanyal, Arun J.
    Gilles, HoChong
    Matherly, Scott C.
    Puri, Puneet
    Luketic, Velimir A.
    Lee, Hannah
    Sterling, Richard K.
    Siddiqui, Mohammad
    HEPATOLOGY, 2016, 64 : 508A - 508A
  • [3] IMPACT OF MODEST WEIGHT REDUCTION ON SERUM MARKERS, LIVER HISTOLOGY, AND DISEASE PROGRESSION IN PATIENTS WITH ADVANCED FIBROSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)
    Bosch, Jaime
    Harrison, Stephen A.
    Ratziu, Vlad
    Anstee, Quentin M.
    Trauner, Michael H.
    Lawitz, Eric J.
    Wong, Vincent Wai-Sun
    Okanoue, Takeshi
    Romero-Gomez, Manuel
    Shiffman, Mitchell L.
    Caldwell, Stephen
    Ma, Lily
    Ding, Dora
    Huss, Ryan
    Chung, Chuhan
    Myers, Robert P.
    Goodman, Zachary
    Afdhal, Nezam H.
    Younossi, Zobair M.
    Sanyal, Arun J.
    HEPATOLOGY, 2021, 74 : 155A - 156A
  • [4] Characterization of insulin resistance in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH)
    Ratziu, Vlad
    Sanyal, Arun J.
    Loomba, Rohit
    Caldwell, Stephen H.
    Ghalib, Reem H.
    Torres, Dawn M.
    McCullough, Arthur J.
    Muir, Andrew J.
    Myers, Robert P.
    Schall, Raul E. Aguilar
    Subramanian, Mani
    McHutchison, John G.
    Bosch, Jaime
    Harrison, Stephen A.
    Abdelmalek, Manal F.
    HEPATOLOGY, 2015, 62 : 1298A - 1299A
  • [5] CHANGES IN FIBROSIS, BUT NOT THE NAFLD ACTIVITY SCORE (NAS), ARE ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS
    Sanyal, Arun
    Harrison, Stephen A.
    Ratziu, Vlad
    Abdelmalek, Manal F.
    Diehl, Anna Mae
    Caldwell, Stephen H.
    Shiffman, Mitchell L.
    Aguilar, Raul
    Jia, Catherine
    McColgan, Bryan J.
    Natha, Macky
    Myers, Robert P.
    Subramanian, Mani
    McHutchison, John
    Muir, Andrew J.
    Afdhal, Nezam H.
    Bosch, Jaime
    Goodman, Zachary
    GASTROENTEROLOGY, 2017, 152 (05) : S1055 - S1055
  • [6] Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
    Sanyal, A.
    Harrison, S.
    Ratziu, V.
    Abdelmalek, M.
    Diehl, A.
    Caldwell, S.
    Shiffman, M.
    Aguilar, R.
    Jia, C.
    McColgan, B.
    Myers, R.
    Subramanian, M.
    McHutchison, J.
    Muir, A.
    Afdhal, N.
    Bosch, J.
    Goodman, Z.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S2 - S3
  • [7] Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
    Harrison, Stephen A.
    Abdelmalek, Manal F.
    Diehl, Anna Mae
    Caldwell, Stephen
    Shiffman, Mitchell L.
    Ghalib, Reem
    Lawitz, Eric
    Rockey, Don C.
    Schall, Raul E. Aguilar
    Jia, Catherine
    McColgan, Bryan J.
    Myers, Robert P.
    Subramanian, Mani
    McHutchison, John G.
    Muir, Andrew J.
    Ratziu, Vlad
    Afdhal, Nezam H.
    Goodman, Zachary D.
    Bosch, Jaime
    Sanyal, Arun J.
    HEPATOLOGY, 2017, 66 : 1120A - 1121A
  • [8] Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
    Younossi, Zobair M.
    Stepanova, Maria
    Noureddin, Mazen
    Kowdley, Kris V.
    Strasser, Simone I.
    Kohli, Anita
    Ruane, Peter
    Shiffman, Mitchell L.
    Sheikh, Aasim
    Gunn, Nadege
    Caldwell, Stephen H.
    Huss, Ryan S.
    Myers, Robert P.
    Wai-Sun Wong, Vincent
    Alkhouri, Naim
    Goodman, Zachary
    Loomba, Rohit
    HEPATOLOGY COMMUNICATIONS, 2021, 5 (07) : 1201 - 1211
  • [9] Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
    Bril, Fernando
    McPhaul, Michael J.
    Caulfield, Michael P.
    Clark, Virginia C.
    Soldevilla-Pico, Consuelo
    Firpi-Morell, Roberto J.
    Lai, Jinping
    Shiffman, Dov
    Rowland, Charles M.
    Cusi, Kenneth
    DIABETES CARE, 2020, 43 (02) : 290 - 297
  • [10] Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis
    Yu, Anthony
    Ritenour, Alexandra
    Vincent, Jennifer
    Park, Chanhyun
    Rascati, Karen
    Godley, Paul
    POSTGRADUATE MEDICINE, 2024, 136 (01) : 14 - 21
12345